Company Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications.
The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications.
Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jun 15, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Jayson Rieger |
Contact Details
Address: 44 West Gay Street, Suite 400 West Chester, Pennsylvania 19380 United States | |
| Phone | 484 453 3300 |
| Website | verrica.com |
Stock Details
| Ticker Symbol | VRCA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001660334 |
| CUSIP Number | 92511W207 |
| ISIN Number | US92511W2070 |
| Employer ID | 46-3137900 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jayson M. Rieger M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| John J. Kirby CPA | Interim Chief Financial Officer |
| David Zawitz | Chief Operating Officer |
| Eugene Scavola | Executive Vice President of Technical Operations |
| Dr. Bradley J. Catalone MBA, Ph.D. | Head of Drug Development |
| Dr. Noah L. Rosenberg M.D. | Chief Medical Officer |
| Chris Chapman | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 20, 2026 | ARS | Filing |
| Apr 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 20, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 11, 2026 | 10-K | Annual Report |
| Mar 11, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 29, 2026 | SCHEDULE 13G/A | Filing |
| Dec 30, 2025 | SCHEDULE 13D/A | Filing |
| Dec 30, 2025 | 8-K | Current Report |
| Dec 23, 2025 | EFFECT | Notice of Effectiveness |